210 related articles for article (PubMed ID: 8908525)
1. Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome.
Gökmen O; Senöz S; Gülekli B; Işik AZ
Gynecol Endocrinol; 1996 Aug; 10(4):249-55. PubMed ID: 8908525
[TBL] [Abstract][Full Text] [Related]
2. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.
Mastorakos G; Koliopoulos C; Creatsas G
Fertil Steril; 2002 May; 77(5):919-27. PubMed ID: 12009344
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives.
Porcile A; Gallardo E
Fertil Steril; 1991 May; 55(5):877-81. PubMed ID: 1827074
[TBL] [Abstract][Full Text] [Related]
4. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism.
Erenus M; Yücelten D; Gürbüz O; Durmuşoğlu F; Pekin S
Fertil Steril; 1996 Aug; 66(2):216-9. PubMed ID: 8690104
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
Falsetti L; Galbignani E
Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
[TBL] [Abstract][Full Text] [Related]
6. Spironolactone as a single agent for long-term therapy of hirsute patients.
Spritzer PM; Lisboa KO; Mattiello S; Lhullier F
Clin Endocrinol (Oxf); 2000 May; 52(5):587-94. PubMed ID: 10792338
[TBL] [Abstract][Full Text] [Related]
7. The influence of combined cyproterone acetate-ethinyl oestradiol therapy on serum levels of dehydroepiandrosterone, androstenedione, and testosterone in hirsute women.
Frölich M; Lachinsky N; Moolenaar AJ
Acta Endocrinol (Copenh); 1977 Feb; 84(2):333-42. PubMed ID: 138326
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
Falsetti L; Pasinetti E
Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
[TBL] [Abstract][Full Text] [Related]
9. Recurrence rate of hirsutism after 3 different antiandrogen therapies.
Yücelten D; Erenus M; Gürbüz O; Durmuşoğlu F
J Am Acad Dermatol; 1999 Jul; 41(1):64-8. PubMed ID: 10411413
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome.
Bhattacharya SM; Jha A
Fertil Steril; 2012 Oct; 98(4):1053-9. PubMed ID: 22795636
[TBL] [Abstract][Full Text] [Related]
11. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
Leelaphiwat S; Jongwutiwes T; Lertvikool S; Tabcharoen C; Sukprasert M; Rattanasiri S; Weerakiet S
J Obstet Gynaecol Res; 2015 Mar; 41(3):402-10. PubMed ID: 25319761
[TBL] [Abstract][Full Text] [Related]
12. Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism.
Nakhjavani M; Hamidi S; Esteghamati A; Abbasi M; Nosratian-Jahromi S; Pasalar P
Br J Clin Pharmacol; 2009 Oct; 68(4):634-7. PubMed ID: 19843067
[TBL] [Abstract][Full Text] [Related]
13. Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism.
Karrer-Voegeli S; Rey F; Reymond MJ; Meuwly JY; Gaillard RC; Gomez F
Medicine (Baltimore); 2009 Jan; 88(1):32-45. PubMed ID: 19352298
[TBL] [Abstract][Full Text] [Related]
14. Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism.
De Leo V; Fulghesu AM; la Marca A; Morgante G; Pasqui L; Talluri B; Torricelli M; Caruso A
Gynecol Endocrinol; 2000 Dec; 14(6):411-6. PubMed ID: 11228061
[TBL] [Abstract][Full Text] [Related]
15. Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on clinical signs of androgenization, hormone profile and ovarian size in patients with polycystic ovary syndrome.
Prelević GM; Würzburger MI; Balint-Perić L; Puzigaća Z
Gynecol Endocrinol; 1989 Dec; 3(4):269-80. PubMed ID: 2516704
[TBL] [Abstract][Full Text] [Related]
16. 17-Hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities.
Maier PS; Mattiello SS; Lages L; Spritzer PM
Gynecol Endocrinol; 2012 Aug; 28(8):606-10. PubMed ID: 22329763
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial.
Kahraman K; Sükür YE; Atabekoğlu CS; Ateş C; Taşkın S; Cetinkaya SE; Tolunay HE; Ozmen B; Sönmezer M; Berker B
Arch Gynecol Obstet; 2014 Aug; 290(2):321-8. PubMed ID: 24676694
[TBL] [Abstract][Full Text] [Related]
18. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
Diri H; Karaburgu S; Acmaz B; Unluhizarci K; Tanriverdi F; Karaca Z; Kelestimur F
Gynecol Endocrinol; 2016; 32(1):42-5. PubMed ID: 26370923
[TBL] [Abstract][Full Text] [Related]
19. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
Falsetti L; Dordoni D; Gastaldi C; Gastaldi A
Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
[TBL] [Abstract][Full Text] [Related]
20. Effects of an oral contraceptive containing cyproterone acetate (Diane-35) on the symptoms, hormone profile, and ovarian volume of hirsute women with polycystic ovarian syndrome.
Prelević GM; Puzigaća Z; Balint-Perić LA
Ann N Y Acad Sci; 1993 May; 687():255-62. PubMed ID: 8323181
[No Abstract] [Full Text] [Related]
[Next] [New Search]
